Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US
Under the agreement, Lupin and its US unit will pay Astellas $90 million, including a $75 million upfront payment and per-unit licensing fees on Mirabegron sales through September 2027